 |
 |
Guilford to Present at CIBC World Markets Annual Biotech & Specialty Pharmaceuticals Conference BALTIMORE, April 27 /PRNewswire-FirstCall/ -- Guilford Pharmaceuticals Inc. (Nasdaq: GLFD) announced today that it will present at the CIBC World Markets Annual Biotech & Specialty Pharmaceuticals Conference on Wednesday, April 28, 2004 at 9:00 a.m. EDT at the Millennium Broadway Hotel in New York, NY. Guilford's Chairman, President and CEO, Craig R. Smith, M.D. will provide an update on the Company's business as well as new developments on products currently in the pipeline. To access the live audio broadcast or the subsequent archived recording log on to http://www.guilfordpharm.com The link for the webcast is located under the Investor Relations section of the website under "conferences." Please connect to the website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary. About Guilford Guilford Pharmaceuticals Inc. is a fully integrated pharmaceutical company engaged in the research, development and commercialization of products that target the hospital market. Presently, Guilford markets two commercial products, GLIADEL(R) Wafer (polifeprosan 20 with carmustine implant), for the treatment of brain cancer, and AGGRASTAT(R) Injection (tirofiban hydrochloride), a glycoprotein GP IIb/IIIa receptor antagonist used for the treatment of acute coronary syndrome (ACS). Guilford's product pipeline includes a novel anesthetic, AQUAVAN(R) Injection, and drugs for treating Parkinson's disease and post-prostatectomy erectile dysfunction. CONTACT: Stacey Jurchison, Director, Corporate Communications, Guilford Pharmaceuticals, (410) 631-5022; [log in to unmask] http://www.guilfordpharm.com SOURCE: PR Newswire (press release) http://tinyurl.com/2r78p * * * ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn